Bioworld Technology CO., Ltd.



CYP2D6 (A300) Peptide

Cat No.: BS5684P

Background

Enhanced CYP2D6 activity has been related to malignancies of the bladder, liver, pharynx, and stomach and, especially, to cigarette-smoking-induced lung cancer. The data suggests that enhanced CYP2D6-mediated metabolism of one or more dietary and other environmental agents, to form a reactive intermediate, plays a role in cancer initiation and/or promotion in various tissues. CYP2D6 polymorphism, which is responsible for the variation in metabolism of debrisoquine 4-hydroxylase, is important in the metabolism of more than 30 drugs and environmental chemicals, including as much as 20% of all commonly prescribed drugs.

Swiss-Prot

P10635

Applications

Blocking

Specificity

This peptide can be used with studies using BS5684 CYP2D6 (A300) pAb.

Purification & Purity

Synthetic peptide CYP2D6 (A300). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at $4 \,^{\circ}{\rm C}$ short term. Aliquot and store at $-20 \,^{\circ}{\rm C}$ long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.